Fate Therapeutics (FATE) PT Lowered to $116 at Stifel on ProTmune Discontinuation
Tweet Send to a Friend
Stifel analyst Benjamin Burnett lowered the price target on Fate Therapeutics (NASDAQ: FATE) to $116.00 (from $118.00) after ProTmune missed ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
